Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Acta Biomater. 2013 Oct 9;10(4):1542–1557. doi: 10.1016/j.actbio.2013.10.001

Fig. 6.

Fig. 6

Use of self-assembling chimeric polypeptide-doxorubicin (CP-Dox nanoparticles for tumor therapy. (A) Concentration of free Dox and CP-Dox in the tumor at 2 and 24 hours after systemic injection. (B) Concentration of Dox and CP-Dox in heart tissues at 2 and 24 hours. (C) Tumor volume after administration of Dox and CP-Dox 15 days after implantation. A substantial increase in animal survival was correlated with administration of CP-Dox. Laser scanning confocal microscopy images of C26 cells (blue) showing cellular uptake of CP-Dox (red) at (D) 5 min, (E) 30 min and (F) 24 hours. Scale bar: 20 µM. Reprinted by permission from Macmillan Publishers Ltd: Nature Materials [150], copyright 2009.